Dr. Paul Jenkins

Dr. Jenkins’ lab is revealing how disruptions to ankyrin scaffolding proteins contribute to psychiatric disorders, identifying novel molecular targets for treatment.

Dr. Jeremy Jenkins is the Pfizer Upjohn Research Professor of Molecular Pharmacology and Associate Chair for Education in the Department of Pharmacology at the University of Michigan Medical School, where he also holds appointments in Psychiatry and the Heinz C. Prechter Bipolar Research Program. His research focuses on the cellular and molecular mechanisms underlying complex psychiatric and neurodevelopmental disorders, with a particular emphasis on how disruptions to ankyrin scaffolding proteins contribute to brain dysfunction. Dr. Jenkins earned his Ph.D. from the University of Michigan and completed postdoctoral training at Duke University. His NIH-funded lab integrates genetics, imaging, biochemistry, and electrophysiology and has been recognized by the Brain & Behavior Research Foundation, One Mind, SFARI, and others.